Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal ...

Liver diseases, especially fatty liver, are rising fast, even among non-drinkers. Liver specialist Dr Saurabh Sethi shares 9 ...

Liver diseases, especially fatty liver, are rising fast, even among non-drinkers. Liver specialist Dr Saurabh Sethi shares 9 ...

Traditional cardiovascular risk assessment tools underperform among individuals with metabolic dysfunction-associated steatotic liver disease.

Introduction Liver cirrhosis and other chronic liver diseases is a serious public health problem, and its incidence, morbidity, and mortality have increased in recent years (1). In 2019, 1691.0 ...

A report into the timeliness of compensation for those infected and affected is due to be published on Wednesday, following ...

Liver cirrhosis is a serious condition. It damages the liver over time. Common causes include alcohol, hepatitis, and fatty ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one in three adults around the globe. It ...

We wanted to find out if rifaximin could be used to prevent and treat hepatic encephalopathy in people with cirrhosis; whether it does this better than no drug treatment, a dummy pill (placebo), or ...

Kennedy Jr. and the members of his newly appointed vaccine panel are casting doubt on the hepatitis B vaccine and the ...

It's well-documented that Americans began drinking more during the pandemic. In Wisconsin, alcohol-related deaths increased ...